ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO703

Minimal Change Disease Management and Outcomes: Observation Over 10 Years From a Single Adult Nephrology Centre

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Oklopcic, Anja, Sheffield Kidney Institute, Sheffield, United Kingdom
  • Bowers, Corrie, Sheffield Kidney Institute, Sheffield, United Kingdom
  • Balasubramanian, Nithin, The University of Sheffield Medical School, Sheffield, Sheffield, United Kingdom
  • Khwaja, Arif, Sheffield Kidney Institute, Sheffield, United Kingdom
  • Salam, Syazrah, Sheffield Kidney Institute, Sheffield, United Kingdom

Minimal change disease (MCD) is one of the causes of nephrotic syndrome. Disease response to corticosteroid varies and time to disease remission and relapse is unknown. We assessed: the remission and relapse rates,time from remission to first relapse, the proportion of patients on adjunct treatment, the proportion of patients with acute kidney injury( AKI) at initial presentation, clinical outcomes.


Single centre service evaluation. Adult patients with diagnosis of MCD. Between 1st January 2010 and 31st December 2019. Follow up data were collected until 31st December 2020.Patients from paediatric nephrology services were excluded


41 patients (26 men, 15 women). All but one had histological diagnosis. Mean age 49 ± 17 years. 11 patients had AKI at presentation. 37/41 patients achieved remission; 26 had complete and 11 had partial remission. 24/37 patients relapsed but all subsequently achieved remission (21 complete and 3 partial remission). The median time from initial remission to first relapse was 168 days (IQR 71 – 327 days). 14/24 patients had a relapse within 6 months from initial remission. All patients received corticosteroid. Additional immunosuppression was predominantly calcineurin inhibitor (CNI, 22 patients).


Majority of MCD patients achieved remission, but over half relapsed within 6 months of initial remission. CNI is the most common adjunct treatment in our centre. Long term dialysis and death are uncommon.


  • Government Support – Non-U.S.